Board Member
Keros Therapeutics, Inc. (KROS)Chairman
Keros Therapeutics, Inc. (KROS)Equibles does not estimate personal net worth.
Get an email with a short summary when Keros Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get KROS alertsJasbir Seehra is recorded as Chairman at Keros Therapeutics, Inc. (KROS) since July 1, 2024 and Board Member and CEO at Keros Therapeutics, Inc. (KROS). The newest filing on record that lists Jasbir Seehra as CEO at Keros Therapeutics, Inc. (KROS) is dated April 22, 2026. The newest filing on record that lists Jasbir Seehra as Board Member at Keros Therapeutics, Inc. (KROS) is dated April 17, 2024. Earlier roles on record: Board Member at Eloxx Pharmaceuticals, Inc. (ELOX) until July 1, 2022. Keros Therapeutics, Inc. reported in an 8-K filed August 6, 2025 that Jasbir Seehra resigned as Chair of the Board, effective August 18, 2025. Keros Therapeutics, Inc. reported in an 8-K filed August 6, 2025 that Jasbir Seehra was appointed President, effective August 18, 2025. Keros Therapeutics, Inc. reported in an 8-K filed June 17, 2024 that Jasbir Seehra was appointed Chair of the Board, effective July 1, 2024. Equibles holds 4 filed executive changes naming Jasbir Seehra; each is listed under recent activity with its source filing. The proxy statement of Keros Therapeutics, Inc. reports total compensation of $2,540,204 for Jasbir Seehra in fiscal 2025, including a base salary of $700,000. Disclosed compensation is on record for 7 fiscal years. Jasbir Seehra has spoken on 1 investor event across 1 company, most recently for Keros Therapeutics, Inc. on June 8, 2026. Keros Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Keros Therapeutics, Inc. includes Jean-Jacques Bienaimé (Chairman and Board Member), Annita Tanini (Chief Accounting Officer), Alpna Seth (Board Member) and 3 others.
“Additionally, Dr. Seehra, who currently serves as Chair of the Board, will cease serving in this role, effective as of August 18, 2025, but will continue to serve as a member of the Board.”
“On August 6, 2025, the Board of Directors (the "Board") of the Company appointed Jasbir Seehra, Chief Executive Officer of the Company, to the additional position of President of the Company, effective as of August 18, 2025.”
“Yeah, I think, first of all, we are a company that's been focused on TGR beta biology, and it's a complex area of biology, but we've been working in it through various iterations for the last 25 plus years.”
2024-07-01–present
Start not stated–present
Last confirmed April 17, 2024
Start not stated–present
Last confirmed April 22, 2026
2024-07-01–2025-08-18
Start not stated–2022-07-01
Biotechnology · Healthcare
Board Member, CEO, Chairman
2024-07-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Keros Therapeutics, Inc. (KROS) | President and Chief Executive Officer | $700,000 | $2,540,204 |
| 2024 | Keros Therapeutics, Inc. (KROS) | Ph.D. Chief Executive Officer and Chair | $699,039 | $6,273,192 |
| 2023 | Keros Therapeutics, Inc. (KROS) | Ph.D. Chief Executive Officer and Chair | $649,135 | $8,932,076 |
| 2022 | Keros Therapeutics, Inc. (KROS) | Ph.D. Chief Executive Officer and Chair | $610,817 | $6,460,934 |
| 2021 | Keros Therapeutics, Inc. (KROS) | Chief Executive Officer and Director | $556,800 | $7,233,959 |
| 2020 | Keros Therapeutics, Inc. (KROS) | Chief Executive Officer and Director | $521,014 | $9,500,299 |
| 2019 | Keros Therapeutics, Inc. (KROS) | Chief Executive Officer and Director | $485,100 | $694,519 |
